Endologix, Inc. (NASDAQ:ELGX) – Investment analysts at Leerink Swann reduced their Q3 2017 earnings per share estimates for Endologix in a report released on Thursday. Leerink Swann analyst R. Misra now anticipates that the medical instruments supplier will earn ($0.15) per share for the quarter, down from their prior estimate of ($0.13). Leerink Swann also issued estimates for Endologix’s Q4 2017 earnings at ($0.17) EPS, FY2017 earnings at ($0.60) EPS, FY2018 earnings at ($0.46) EPS, FY2019 earnings at ($0.39) EPS and FY2020 earnings at ($0.24) EPS.

Endologix (NASDAQ:ELGX) last announced its earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.08. Endologix had a negative net margin of 40.77% and a negative return on equity of 44.60%. The business had revenue of $48.60 million during the quarter, compared to the consensus estimate of $47.58 million. During the same quarter last year, the firm earned ($0.20) earnings per share. Endologix’s quarterly revenue was down 4.6% on a year-over-year basis. WARNING: “Q3 2017 Earnings Forecast for Endologix, Inc. Issued By Leerink Swann (NASDAQ:ELGX)” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/08/q3-2017-earnings-forecast-for-endologix-inc-issued-by-leerink-swann-nasdaqelgx.html.

Other equities research analysts have also recently issued research reports about the stock. Stifel Nicolaus reissued a “buy” rating and set a $5.50 price target (up previously from $5.00) on shares of Endologix in a research report on Monday, June 5th. Stephens lowered shares of Endologix from an “overweight” rating to an “equal weight” rating and set a $6.00 price objective for the company. in a report on Thursday, May 18th. Royal Bank Of Canada restated a “hold” rating and issued a $8.00 price objective on shares of Endologix in a report on Thursday, April 13th. BMO Capital Markets restated a “hold” rating and issued a $7.00 price objective on shares of Endologix in a report on Tuesday, April 11th. Finally, Zacks Investment Research upgraded shares of Endologix from a “sell” rating to a “hold” rating in a report on Friday, May 5th. One investment analyst has rated the stock with a sell rating and eleven have given a hold rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $6.28.

Shares of Endologix (NASDAQ ELGX) opened at 4.16 on Monday. The company’s market capitalization is $347.05 million. Endologix has a 1-year low of $4.08 and a 1-year high of $13.30. The firm has a 50-day moving average of $4.91 and a 200 day moving average of $6.07.

In related news, Director Guido J. Neels purchased 20,000 shares of the company’s stock in a transaction dated Friday, May 19th. The shares were purchased at an average price of $4.32 per share, with a total value of $86,400.00. Following the acquisition, the director now directly owns 61,380 shares in the company, valued at approximately $265,161.60. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Dan Lemaitre purchased 22,522 shares of the company’s stock in a transaction dated Monday, May 22nd. The shares were bought at an average cost of $4.43 per share, for a total transaction of $99,772.46. Following the acquisition, the director now owns 68,689 shares in the company, valued at $304,292.27. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 44,722 shares of company stock valued at $195,676. 4.10% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP bought a new stake in shares of Endologix during the first quarter worth about $160,000. Emerald Advisers Inc. PA acquired a new position in Endologix during the first quarter worth about $222,000. Quantitative Systematic Strategies LLC acquired a new position in Endologix during the first quarter worth about $261,000. MARSHALL WACE ASIA Ltd acquired a new position in Endologix during the first quarter worth about $323,000. Finally, Marshall Wace North America L.P. acquired a new position in Endologix during the first quarter worth about $323,000.

Endologix Company Profile

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Earnings History and Estimates for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.